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Abstract: Objective: Kaposi’s sarcoma (KS),
first described in 1872 by Moritz Kaposi, is a
spindle cell, multifocal vascular tumor. Despite
the intense work on the pathogenesis of KS,
its etiology remains in doubt. The aim of this
study was to determine the presence of HHV8 sequences in non-HIV associated Kaposi’s
sarcoma patients, namely classical and
immunosuppression-associated, and compare
the results with normal healthy subjects.
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Materials and Methods: Nineteen patients
with classical Kaposi’s sarcoma (CKS), and
nine patients with immunosuppressionassociated Kaposi’s sarcoma (ISKS) (6 renal
transplantation, 1 Behçet’s disease, 1 high
grade lymphoma, 1 ataxia telangiectasia)
were included in this study. Skin samples of
29 healthy subjects who had elective plastic
surgery were used as a control group. All
samples were retrieved from the archives of
the pathology department and studied in the
microbiology department of a university
hospital. Formalin fixed, paraffin embedded
tissue
samples
of
classical
and
immunosuppression-associated
Kaposi’s
sarcoma patients were investigated by

Introduction
Kaposi’s sarcoma (KS), first described in 1872 by
Moritz Kaposi, is a spindle cell, multifocal vascular tumor
that occurs in the lymphoid and respiratory system and
gastrointestinal tract as well as in the skin (1-3). Four
different epidemiologic forms of Kaposi’s sarcoma have
been
described:
classical,
African
endemic,
immunosuppression-associated,
and
human
immunodeficiency virus infection-associated Kaposi’s
sarcoma (AIDS-KS) (4).
Despite the intense work on the pathogenesis of KS,
its etiology remains in doubt. Formerly CMV, HBV, HAV,
HHV-6, HIV-tat, and HPV were incriminated as etiologic
agents in KS (5-9). Recently herpesvirus-like viral
particles have been detected initially in HIV-associated

polymerase chain reaction (PCR) and
restriction enzyme analysis (REA) for the
presence of HHV-8 DNA sequences.
Results: HHV-8 sequences were detected in
16 of 19 (84%) CKS patients, and 5 of 9
(55%) ISKS patients by PCR and REA. The
prevalence of HHV-8 detection was lower in
the ISKS group. In this group, five positive
results belonged to renal transplant patients
who received cyclosporine in addition to
prednisolone. We did not detect HHV-8
sequences in the 29 healthy skin samples.
Conclusions: Our data suggest that HHV-8
probably plays an important role in the
pathogenesis of non-HIV infection related
forms of KS. Unlike other herpesviruses,
HHV-8 is not widespread in the normal
population. In immunosuppressed patients,
HHV-8 expression may be due to cyclosporine
treatment.

Key Words: Kaposi’s sarcoma, Human
herpesvirus-8

Kaposi’s sarcoma by representational difference analysis
(10). Thereafter these sequences were described in other
forms of KS by PCR and other methods (11-18). To date,
HHV-8 has been definitively associated with two more
human diseases: primary effusion lymphoma and
multicentric Castleman’s disease (20,21). This virus,
designated as KSHV and later renamed HHV-8, shows
tegument and capsid homologies with the Gamma
herpesvirus family (10).
The aim of this study was to determine the HHV-8
DNA in Turkish patients with two HIV-unrelated forms of
Kaposi’s sarcoma, namely CKS and ISKS, and the
diagnostic utility of PCR in formaline fixed paraffin
embedded skin samples. We also analyzed the prevalence
of this new virus in a control group that consisted of 29
HIV seronegative healthy subjects.
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Materials and Methods
Forty archival KS specimens, obtained between 1987
and 1997, were retrieved from the department of
pathology of Hacettepe University, Faculty of Medicine,
Ankara, Turkey. Twenty-eight of the specimens
demonstrating active KS lesions were selected for the
study. Patients were divided into two groups according to
their immune status. Among the selected patients, 19 had
CKS (Group 1) and 9 had ISKS (Group 2). In the second
group, 6 of them were renal transplant patients receiving
cyclosporine and prednisolone. Patients other than renal
transplantation patients that were categorized as having
ISKS were as follows: one patient with Behçet’s disease
taking prednisolone for two years, one patient with high
grade lymphoma who developed KS after receiving
radiotherapy and chemotherapy, and one patient with
ataxia telangiectasia who developed KS at 12 years of
age. Although they were immunocomppromised by
different causes they were included in the ISKS group.
The
duration
between
the
initiation
of
immunosuppressive therapy and the development of
Kaposi’s sarcoma are shown in the Table. All patients
were serologically HIV negative. Control skin samples
were obtained from 29 healthy subjects undergoing
elective plastic surgery.
DNA was extracted from formalin fixed, paraffin
embedded and fresh tissues. Paraffin embedded tissue
blocks were cut into 50 mm sections. In order to prevent
contamination and false positive results, the microtome
knife was cleaned with xylene after each sample and
sterile disposable pipettes and separate pairs of gloves
were used. DNA on the contaminated surfaces was
Table.

destroyed using UV germicide lamps. The sections were
deparaffinized twice by adding 1 ml xylene, mixed with a
vortex for 5 seconds, shaken for 30 minutes, and then
centrifuged for 5 minutes in a microcentrifuge at 12,000
g in order to precipitate tissues. Xylene was removed by
adding 1 ml of 95% ethanol, and centrifugating and
decanting the tubes in order to remove all of the paraffin
which might inhibit the amplification reaction. The tissues
were resuspended in 100 µl digestion buffer containing
50 mM Tris pH 8.5, 1 mM EDTA, 5% Tween 20, and
proteinase K 200 µg/ml, and incubated overnight at
37°C. The next morning the tubes were incubated for 20
minutes on boiling water, and the debris was sedimented
by spinning at 12,000 g for 5 minutes. The supernatant
containing DNA was transferred to a clean tube and
stored at –20°C until used for PCR. The primers used in
this study were first described by Chang et al. and were
specific for HHV-8. 5’TCCGTGTTGTCTACGTCCAG3’ was
used
as
the
first
primer,
and
5’AGCCGAAAGGATTCCACCAT3’ was used as the second
(10). A positive control containing HHV-8 DNA obtained
from a patient with HIV-associated KS was kindly
provided by Dr. Friedman-Kien from NYU. Restriction
enzyme analysis (REA) was used to verify that amplified
DNA belonged to HHV-8. Restriction enzyme cutting sites
were analyzed, and Pst-I restriction enzyme was selected.
Amplified DNA was cut into two DNA fragments of 95
and 138 base pairs by this enzyme. All samples were
studied in double blind fashion. After DNA amplification
and restriction, digestion products were run on a
polyacrilamide gel electrophoresis, stained by ethidium
bromide, visualized and photographed over a UV
transilluminator (Figures 1-2).

Clinical features and results of HHV-8 DNA amplification by
PCR and REA in ISKS patients.

GROUP II
PN

S

A

PCR/REA

TI

T(Month)

1
2
3
4
5
6
7
8
9

F
F
F
F
F
M
M
M
F

40
45
15
51
31
46
51
28
12

+
+
+
+
+
-

RT
RT
RT
RT
RT
RT
HL
BD
AT

9
12
8
48
9
10
8
24
144

PN: Patient number, S: Sex, A: Age, TI: Type of immunosuppression,
T: Duration before KS, RT: Renal transplantation, HL: High Grade
Lymphoma, BD: Behcet’s Disease, AT: Ataxia Telangiectasia.
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Figure 1.

PCR amplification and REA of HHV-8 sequences from CKS
patients. M: Molecular DNA weight marker, Lane 1:
Positive control marker, Lane 2: REA of positive control,
Lanes 3, 5: PCR amplification of the first and the second
patients with CKS, Lanes 4, 6: REA of the same patients,
Lanes 7, 8: Negative PCR and REA results of the third
patient.
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whatever the epidemiologic group. So there is
widespread consensus that this virus is universally
present in KS lesions (10-20). Similar to other studies,
we detected HHV-8 DNA in lesional tissue samples of 16
of the 19 classical KS (84%) and 5 of the 9 (55%)
immunosuppression associated KS patients by PCR. Our
data confirms the presence of HHV-8 in HIV-unrelated
forms of KS, namely CKS and ISKS, in Turkish patients.
Lack of 100% positivity in CKS has been reported
repeatedly by other researchers (22) as well in our study,
and this sequence suggests the interplay of the underlying
immunodeficiency in the expression of HHV-8 in CKS
lesions. The relatively low detection rate of HHV-8 in
these samples may be attributed to sequence variation,
low copy number in the biopsy specimens or the absence
of this virus in some of the lesions (12).
Figure 2.

PCR amplification and REA of HHV-8 sequences from ISKS
patients. M: Molecular DNA weight marker, Lane 1:
Negative control sample (H2O), Lanes 2, 4: PCR
amplification of the first and the second patients in ISKS
group. Lanes 3, 5: REA of the same patients.

Results
All biopsy specimens from patients with KS and
healthy subjects were analyzed by PCR. In the first group
there were 11 male and 8 female patients; the mean age
was 54.89 (standard deviation 19.16, range 17-80). In
the second group there were 6 female and 3 male
patients; the mean age was 35.44 (standard deviation
14.79, range 12.51). PCR and subsequent REA revealed
the presence of HHV-8 DNA in 16 of the 19 classical KS
patients and 5 of the 9 immunosuppression associated KS
patients. The prevalence of HHV-8 was 84% in the first
group, and 55% in the second. In the second group, 5
positive results belonged to the renal transplant patients
who received cyclosporine in addition to prednisolone. In
only one patient with renal transplantation receiving
cyclosporine plus prednisolone could we not demonstrate
HHV-8 particles with PCR amplification. None of the
control samples were positive for HHV-8 DNA by PCR. In
all positive samples, REA with Pst-I showed expected
restriction fragments as 138 and 95 base pairs.

Discussion
After HHV-8 was described in HIV-associated KS,
several authors have investigated the presence of this
virus in other forms of KS. The great majority of KS
samples were positive for the presence of this virus

Herman et al., in a recent study, showed that paraffin
embedded tissues are satisfactory for HHV-8 detection by
PCR (22). Foreman et al. described distinct HHV-8
sequences in Saudi Arabian patients (23). Similarly, in our
study, at least in some of the specimens, sequence
variation seems to be responsible for the low detection
rate rather than other factors.
ISKS was first recognized in 1950’s with the
introduction of immunosuppressive treatment for organ
transplantation and other diseases such as autoimmune
diseases, bullous diseases and atopic dermatitis (4,2426). HHV-8 presence has been described in
immunosuppression associated epithelial malignancies as
well as ISKS (17). Rady et al. have investigated HHV-8
presence in 33 epithelial tumors of 4 organ transplant
patients receiving cyclosporine, and showed the presence
of HHV-8 in 82% by PCR (27). However, Wolf et al.
could not show the presence of HHV-8 in premalignant
and malignant skin lesions of patients receiving PUVA
treatment. They proposed that HHV-8 is not a
widespread latent virus and is activated by
immunosuppression like other herpesviruses (28). Jensen
et al. showed HHV-8 sequences in 11 of 14 patients, in
three different forms of Kaposi’s sarcoma, by PCR. Three
of the positive results belonged to ISKS patients but the
medications of these patients are not mentioned (29).
Rady et al., in their recent study, investigated the
presence of HHV-8 in 11 patients (7 with
immunosuppression associated KS and 4 with organ
transplantation associated KS). They found HHV-8 in
100% of specimens and confirmed it by Southern blot
analysis (30).
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In our second group, we did not detect HHV-8 DNA
by PCR in patients other than renal transplantation
patients. This discrepancy may be due to different types
of immunosuppression. On the other hand, in the ISKS
group, patients other than renal transplantation patients
developed KS without activation of HHV-8.
In the second group, one of the patients was
diagnosed with ataxia telangiectasia and developed KS at
12 years of age. Although she did not receive
immunosuppressive treatment, we considered this patient
to be immunocomppromised because AT is a congenital
immunosuppressive disease. On the other hand, one
patient with Behçet’s disease developed KS within two
years of the beginning of corticosteroid therapy. In both
cases, we did not detect HHV-8 DNA.
Among immunosuppressive therapies, cyclosporine
may have a peculiar effect, because in cyclosporine using
renal transplant patients, development of KS is seen
earlier than in patients using conventional therapies (4).
The prevalence of HHV-8 infection or latency in
Turkey is not known, since no population based studies
have been performed yet. If this virus contributes
etiologically to KS, these sequences should be found in
lesions across all geographic distributions. Dupin et al., in
a recent study, showed that HHV-8 is not prevalent in
non-KS skin diseases or in healthy control subjects and
concluded that HHV-8 is not prevalent in France (31).
Similarly, Herman et al. were unable to show HHV-8
sequences in non-KS dermatologic lesions of HIV negative
patients by PCR (22). However, Monini et al. showed
HHV-8 sequences in prostate and seminal tissue fluids of
immunocompetant individuals and proposed that HHV-8,
like other herpesviruses, is widespread in their population
(32). In our control group, the absolute negativity of
HHV-8 suggests that this virus does not appear to be
widespread in our geographic region. Our results are in
corroboration with Dupin and Herman et al. On the other
hand, Cattani et al. found HHV-8 positivity in 23% of
healthy control subjects in Italian patients and concluded
that HHV-8 could be a widespread virus at least in the
Mediterranean regions where CKS is prevalent (33).
There are some reports about the distribution of this
virus. Its presence in body cavity based lymphomas,
multicentric Castleman’s disease and genital tissues of
non-HIV infected patients showed that this virus is not
exclusively restricted to KS lesions, but is widespread in
other tissues like other herpesviruses (20,21,32,34).
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Whitby et al. showed that HHV-8 genomes are
detectable in the blood of KS negative, HIV positive gay
men and that their presence is strongly predictive of later
development of KS (35). Geographically the detection of
HHV-8 antibodies is associated with high incidence areas
for KS (36). The prevalence of the virus is generally high
in those human populations with a high incidence of KS,
and the virus carries the tools to stimulate cell
proliferation and to induce neovascularization (37).
A review of 21 published studies involving 549
patients, with all forms KS from various parts of the
world, shows that HHV-8 DNA can be detected on
average 95% of the time in KS lesions by PCR. It is now
clearly established using a variety of techniques that HHV8 is not only restricted to KS lesions, and viral DNA and
RNA are detectable in most KS tumor spindle cells. To
date, published assays show similar epidemiologic trends,
despite important differences in their sensitivities and
specifities. The relative HHV-8 seroprevalence measured
by these assays matches the patients for KS risk groups
among patients with AIDS and the patterns for non-HIV
related KS incidence among patients from various
countries (38).
For HHV-8 to be causally related to KS, infection must
precede the onset of disease. This is an absolute criterion
for causality and both seroconversion and DNA based
detection studies provide evidence for KSHV infection
among most AIDS-KS patients prior to disease onset
(38).
Studies on HHV-8 now indicate that it is not a
ubiquitous infection in most human populations, although
high rates of infection in some populations may account
for early studies suggesting widespread HHV-8 infection
(38).
In conclusion, our results, like those of previous
studies, suggest that this virus may play an important role
either directly or indirectly in the pathogenesis of KS. But
HHV-8 infection is not prerequisite for the development
of KS; other factors, environmental or genetic, are
required.
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